Unum Therapeutics, a Cambridge, Massachusetts-based clinical stage biopharmaceutical company developing cellular immunotherapies for the treatment of many different cancers, received a $15 million credit facility.
Square 1 Bank, a division of Pacific Western Bank, provided the debt financing.
The facility will provide access to growth capital to support strategic initiatives and general corporate purposes.
Led by Charles “Chuck” Wilson, PhD, President & CEO, and Seth Ettenberg, PhD, Chief Scientific Officer, Bio Unum develops combination cancer therapies using recent advances in T-cell engineering and antibody therapeutics. Its proprietary Antibody-Coupled T-Cell Receptor (ACTR) may be used in combination with a variety of cancer-specific antibodies to treat different cancer types. Its lead program is currently undergoing Phase I clinical testing to evaluate safety and efficacy in certain forms of lymphoma.
The company is backed F-Prime Capital, Atlas Venture, New Leaf Venture Partners and Sanofi-Genzyme BioVentures.